US FDA inspection at Caplin Steriles unit ends with 10 procedural observations

Regulatory & Legal View source PDF Explain this filing

CAPLIPOINT · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-3.2%Reaction day

₹2569.70

prior close

₹2545.00

announcement price

After-mkt

timing

Nifty Smallcap 250market-0.2%-3.0% vs market

Pharmaceuticals peers, median of 176sector-0.2%-3.0% vs sector

On the reaction day the stock moved 3.0 pts less than Nifty Smallcap 250 and 3.0 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-1.4

10m

-2.2

15m

-1.2

30m

-1.0

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-3.2-0.2-3.0-0.2-3.0

Next day

-3.9-0.4-3.5-0.4-3.4

-1.8+0.2-2.0-0.0-1.8

-0.8+0.1-0.9+0.0-0.9

-1.9+0.4-2.4+0.5-2.5

-2.8-0.2-2.5+0.5-3.3

+5.9-0.9+6.7+0.7+5.1

15d

+0.1-2.8+2.9+0.4-0.4

+11.1-1.4+12.5+2.0+9.1

-11.6-10.0-1.6-6.4-5.2

—————

UpDownMarket · Nifty Smallcap 250Sector · Pharmaceuticals peers, median of 176Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

US FDA conducted an unannounced inspection at Caplin Steriles' injectable and ophthalmic facility in Gummidipoondi from August 13 to 21, 2026. The facility received Form 483 with 10 observations, all procedural in nature, with no data integrity issues and no repeat observations. The company is addressing the observations and will respond to US FDA within the stipulated timeframe.

Likely market impact

Minor procedural observations, no data integrity issues. Limited near-term impact; company response to US FDA is pending.